Rationale: Adhesive small bowel obstruction (aSBO) is a frequent surgical emergency, associated with 3-8% hospital mortality and a high risk of recurrence (20% at two years of follow-up). ASBO can be treated conservatively or by emergency surgery. In the absence of bowel ischemia or strangulation, conservative treatment is often preferred, to avoid the excess morbidity and mortality from emergency surgery. Recent epidemiological studies, however, demonstrate a considerable higher recurrence risk of aSBO after conservative treatment that is associated with hospital readmissions and lower survival. Elective adhesiolysis following successful conservative treatment might reduce these long-term risks whilst avoiding the high complication rate of emergency surgery. Objective: The investigators aim to assess the efficacy of elective adhesiolysis following conservative treatment for aSBO as compared to the current state of the art (wait-and-see policy) to prevent long-term recurrence of aSBO. Further the investigators will evaluate quality of life, healthcare and societal costs. Study design: Multicenter open-label randomized controlled trial, including 380 patients. Study population: Adult patients who recovered from aSBO by conservative treatment. Patients that are inoperable for medical, anaesthesiological or surgical reasons are excluded. Intervention (if applicable): The intervention of investigation is elective adhesiolysis. Adhesiolysis is an abdominal procedure in which all adhesions are cut, and adhesion prevention applied to reduce the risk of adhesion reformation. The intervention is compared to wait-and-see policy (the current standard treatment) Main study parameters/endpoints: Primary outcome is recurrence, defined as readmission for obstructive systems with aetiology of adhesions confirmed by CT. The investigators hypothesize a 50% reduction in recurrence in the intervention arm. Secondary outcomes are morbidity from surgery, health-related quality of life (EQ5D), healthcare costs and societal costs (iMCQ and iPCQ) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients in the intervention group are exposed to abdominal surgery, which is associated with a moderate risk of minor complications such as wound infection and haemorrhage, and a small risk of severe complications such as iatrogenic bowel injury. According to our hypothesis, a potential benefit is the reduction in the risk of recurrences. Recurrence of aSBO is associated with a risk of readmissions, reinterventions, and also increased long-term mortality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
380
See descriptions in study arms
At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).
UZ Antwerpen
Antwerp, Belgium
Hôpital Erasme
Brussels, Belgium
UZ Brussel
Brussles, Belgium
UZ Leuven (National Coordinating Center)
Leuven, Belgium
Vitaz Sint-Niklaas
Sint-Niklaas, Belgium
ZGT Almelo
Almelo, Netherlands
OLVG Amsterdam
Amsterdam, Netherlands
Maasziekenhuis Pantein Boxmeer
Boxmeer, Netherlands
St. Jansdal Harderwijk
Harderwijk, Netherlands
MaastrichtUMC+
Maastricht, Netherlands
...and 4 more locations
recurrence of ASBO at 2-years of follow-up
Recurrence is defined as a readmission for symptoms of small bowel obstruction, including lower abdominal pain, bloating and nausea with or without vomiting. In addition imaging by CT-scan should not show indications of other causes of bowel obstruction (such as an incarcerated abdominal wall hernia or tumour), which is over 90% accurate for the diagnosis of ASBO.
Time frame: 2 years
Recurrence at 5 year
(identified by record linking\[BE\] or general practitioner data\[NL\])
Time frame: 5 years
Recurrences needing surgery
ASBO recurrence requiring emergency surgery
Time frame: 2 years and 5 years
Morbidity from elective adhesiolysis
Composite of: * Serious adverse events and complications, graded by Clavien-Dindo score. * Intra-operative events (i.e. bowel injury), graded by ClassIntra® * ICU admission * Reinterventions within 90 days
Time frame: 90 days
Health related quality of life
\- Health-related quality of life measured by EQ5D
Time frame: 2 years
Gastro-intestinal related quality of life
\- Gastro-intestinal related quality of life measured by GIQLI
Time frame: 2 years
Healthcare costs
measured by modified iMCQ
Time frame: 2 years
Societal costs
measured by modified iMCQ
Time frame: 2 years
Cost-effectiveness
incremental cost-effectiveness ratio, i.e. cost per QALY
Time frame: 2 years and 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.